Certara, Inc. (NASDAQ:CERT) Position Boosted by Brown Brothers Harriman & Co.

Brown Brothers Harriman & Co. increased its position in Certara, Inc. (NASDAQ:CERT - Free Report) by 63.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 3,818,613 shares of the company's stock after buying an additional 1,487,998 shares during the quarter. Brown Brothers Harriman & Co. owned about 2.37% of Certara worth $40,668,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Venturi Wealth Management LLC raised its holdings in shares of Certara by 839.1% in the 4th quarter. Venturi Wealth Management LLC now owns 2,808 shares of the company's stock worth $30,000 after purchasing an additional 2,509 shares during the period. Blue Trust Inc. lifted its position in Certara by 20.9% during the fourth quarter. Blue Trust Inc. now owns 4,747 shares of the company's stock valued at $56,000 after buying an additional 822 shares in the last quarter. ANTIPODES PARTNERS Ltd grew its stake in Certara by 204.7% during the fourth quarter. ANTIPODES PARTNERS Ltd now owns 5,442 shares of the company's stock worth $58,000 after buying an additional 3,656 shares during the period. KBC Group NV increased its position in shares of Certara by 64.1% in the fourth quarter. KBC Group NV now owns 7,998 shares of the company's stock worth $85,000 after acquiring an additional 3,125 shares in the last quarter. Finally, GAMMA Investing LLC lifted its holdings in shares of Certara by 442.2% during the 4th quarter. GAMMA Investing LLC now owns 8,421 shares of the company's stock valued at $90,000 after acquiring an additional 6,868 shares in the last quarter. Institutional investors and hedge funds own 73.96% of the company's stock.

Remove Ads

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on CERT. Barclays increased their price target on Certara from $12.00 to $13.00 and gave the company an "equal weight" rating in a report on Friday, February 28th. Stephens reiterated an "overweight" rating and set a $17.00 target price on shares of Certara in a report on Thursday, February 27th. TD Cowen began coverage on Certara in a research report on Thursday, February 27th. They set a "buy" rating and a $16.00 price target on the stock. Finally, William Blair reaffirmed a "market perform" rating on shares of Certara in a research report on Thursday, February 27th. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus price target of $15.83.

Certara Stock Up 3.6 %

NASDAQ CERT traded up $0.36 during mid-day trading on Wednesday, reaching $10.23. 679,333 shares of the company's stock traded hands, compared to its average volume of 1,042,388. The company has a current ratio of 2.86, a quick ratio of 2.86 and a debt-to-equity ratio of 0.28. Certara, Inc. has a 1-year low of $9.41 and a 1-year high of $19.18. The company has a fifty day simple moving average of $12.34 and a 200-day simple moving average of $11.44. The company has a market cap of $1.65 billion, a price-to-earnings ratio of -51.15, a P/E/G ratio of 9.29 and a beta of 1.60.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.